Overview

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Status:
Terminated

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborators:

Cancer International Research Group (CIRG)
Genentech, Inc.
Hoffmann-La Roche

Treatments:

Bevacizumab
Carboplatin
Cyclophosphamide
Docetaxel
Epirubicin
Fluorouracil
Trastuzumab